Sun Pharma gets CDSCO panel nod to conduct phase 4 study of Cyclosporine Ophthalmic Solution

Published On 2022-02-27 04:30 GMT | Update On 2022-02-28 07:35 GMT

New Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct a phase 4 clinical trial of Immunomodulator, Cyclosporine Ophthalmic Solution, which is used to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye).

This came in line with the revised phase 4 clinical trial protocol presented by drug giant Sun Pharma at a recent SEC meeting for Ophthalmology.

Sun Pharma has launched Cequa, a cyclosporine ophthalmic solution, 0.09%, which is a calcineurin inhibitor immunosuppressant, belonging to the class, immunosuppressants. The medicine is indicated for patients with keratoconjunctivitis sicca (dry eye), to effectively increase their tear production.

Dry eye diseases affect the ability of the eyes to produce their own tears. It is also used to treat vernal keratoconjunctivitis, an allergic eye condition. Cyclosporine ophthalmic solution, 0.09% is supplied as a sterile, clear, colourless ophthalmic solution for topical ophthalmic use.

The drug is advised to be administered in one drop, twice daily, around 12 hours apart. It is put into each eye using a single-use vial. The solution is suggested to be used immediately after opening, and the vial along with the remaining contents has to be discarded after use.It is not approved for use by patients younger than 16 years old. Aqua is the first and only chronic dry eye treatment composed of NCELL Technology.

At a recent SEC meeting for ophthalmology, dated February 22,2022, the firm presented the proposal to conduct a Phase IV clinical trial of Cyclosporine Ophthalmic Solution 0.09% w/v as per the conditions of the import and marketing permission of the product before the committee.

After detailed deliberation, the committee granted permission to conduct the Phase IV clinical trial as per the protocol.

In addition, the committee suggested the firm submit the result of the Phase IV study for further review.

Also Read:Serdia Pharma bags CDSCO approval for anti-diabetic FDC of extended-release Gliclazide 60mg plus Metformin 1000mg tablet

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma gets CDSCO panel nod to conduct phase 4 study of Cyclosporine Ophthalmic Solution

Similar News

Roche gets negative EMA Committee opinion on Elevidys CMA for 3-7 year olds with Duchenne muscular dystrophy

Expert Committee Clears Ravenbhel to Begin Resmetirom Phase 3 Trial, Asks for BE Data First

Menopause relief drug: USFDA extends review period for Bayer Elinzanetant

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Troikaa's Fast-Acting Paracetamol Shot Hits Regulatory Hurdle, CDSCO Panel Seeks More Data

Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma

Pharma Firm Ignored Safety Gaps Before Deadly Blast, Paid Rs 32 Cr To Victims, Parliament Informed

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma